
Joshua Rosenberg, MD, discuses the differences in clinical trials that enroll both intra-abdominal infection patients and those with hospital- or ventilator-associated pneumonia face major complexity because these two groups differ widely in baseline severity, mortality risk, and expected treatment outcomes

